EGFR and non-small cell lung carcinoma: reported that berberine in combination with ositinib synergistically and selectively reduced the survival of ositinib-resistant EGFR-mutant NSCLC cell lines and enhanced the growth inhibition of met-amplified ositinib-resistant transplanted tumors in nude mice.